Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crestor in hypercholesterolemia (METEOR)
NCT00225589Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2002
- Primary completion
- May 2006
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Rosuvastatin 40 mg with Placebo (2 arms). Primary endpoint: Mean maximum intima media thickness of 12 vessel segments at 2 years. Started Aug 2002; status: completed.
02
Drugs
rosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00225589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225589.